Clinical Trials Logo

Avascular Necrosis clinical trials

View clinical trials related to Avascular Necrosis.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT05980234 Enrolling by invitation - Osteoarthritis Clinical Trials

MDR - Longevity IT Oblique and Offset Liners

Start date: August 30, 2023
Phase:
Study type: Observational

The objective of this retrospective enrollment/prospective follow-up consecutive series PMCF study is to collect data confirming safety, performance, and clinical benefits of the Longevity IT Oblique and Offset liners when used for primary or revision total hip arthroplasty (implants and instrumentation) at a minimum of 10-year follow-up.

NCT ID: NCT05587244 Enrolling by invitation - Clinical trials for Rheumatoid Arthritis

G7 Freedom Constrained Vivacit-E Liners

Start date: May 8, 2023
Phase: N/A
Study type: Interventional

The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Freedom Constrained Vivacit-E Acetabular Liners in primary and revision total hip arthroplasty.

NCT ID: NCT05548972 Enrolling by invitation - Clinical trials for Rheumatoid Arthritis

G7 Dual Mobility With Vivacit-E or Longevity PMCF

Start date: March 20, 2023
Phase: N/A
Study type: Interventional

This study is a global, multi-center, prospective, non-controlled, non-randomized, post-market clinical follow-up study. The main objectives of this study are to confirm the long-term safety, performance, and clinical benefits of the G7 Dual Mobility Acetabular System when used with the Vivacit-E or Longevity polyethylene hip bearing and instrumentation in primary total and revision (total) hip arthroplasty

NCT ID: NCT05500066 Enrolling by invitation - Clinical trials for Rheumatoid Arthritis

AEQUALIS™ FLEX REVIVE™ Study (REVIVE)

REVIVE
Start date: January 11, 2023
Phase:
Study type: Observational

This is an international, single arm, multicenter, prospective, non-significant risk, Post-Market Clinical Follow-up (PMCF) study. Data will be collected for the commercially available AEQUALIS FLEX REVIVE shoulder system in both the anatomic and reversed configurations. The purpose of this study is to collect data needed to satisfy the European Union (EU) Medical Device Regulation (MDR) clinical post-market surveillance (PMS) and reporting requirements, and to support future regulatory submissions and peer-reviewed publications on device performance and safety.

NCT ID: NCT05067543 Enrolling by invitation - Avascular Necrosis Clinical Trials

Perform Humeral System Study

PHS
Start date: September 12, 2021
Phase:
Study type: Observational

The purpose of this study is to collect data needed to satisfy the European Union (EU) Medical Device Regulation (MDR) clinical post-market surveillance (PMS) and reporting requirements, and to support future regulatory submissions and peer-reviewed publications on device performance and safety.

NCT ID: NCT04816773 Enrolling by invitation - Osteoarthritis Clinical Trials

Post Market Clinical Follow-Up Study for EVOLUTION® NitrX™ Keeled Tibia and EVOLUTION® NitrX™ CS/CR Femur With Cruciate Sacrificing Insert

Start date: January 27, 2022
Phase:
Study type: Observational

MicroPort Orthopedics Inc. (MPO) plans to market the EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® NitrX™ CS/CR Non-Porous Femur with the EVOLUTION® Cruciate Sacrificing (CS) Tibial Insert globally, including in the European Union (EU). MPO is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and effectiveness of the EVOLUTION® NitrX™ Non-Porous Keeled Tibia and EVOLUTION® NitrX™ CS/CR Non-Porous Femur. These components are used along with the EVOLUTION® Cruciate Sacrificing (CS) Tibial Insert components that is marketed in the European Union (EU). This type of data collection is required by regulatory authorities for all TKA devices that do not have medium to long-term clinical evidence available.

NCT ID: NCT03040778 Enrolling by invitation - Avascular Necrosis Clinical Trials

Pentoxifylline and Tocopherol (PENTO) in the Treatment of Medication-related Osteonecrosis of the Jaw (MRONJ)

Start date: April 1, 2018
Phase: Phase 3
Study type: Interventional

The overall purpose of this project is to answer the following clinical question: Among Medication-Related Osteonecrosis of the Jaw (MRONJ) patients, do those who are treated with the Pentoxifylline and Tocopherol (PENTO) regimen and standard of care, when compared to those treated with standard of care alone, have decreased areas of exposed bone after one year of treatment?